- COMMUNITY OUTREACH AND ENGAGEMENT (COE) The Ohio State University Comprehensive Cancer Center (OSUCCC) is a national and international leader in translational research, with a reputation for delivering high-quality patient care and effective outreach and education programs to residents of the state of Ohio - our catchment area (CA) - and beyond. The CA includes all 88 counties in Ohio, which have very diverse populations, with many underserved communities as well as urban, rural and Appalachian communities. Electra Paskett, PhD, MSPH (CC) Associate Director for Population Science and Community Outreach and Director of the Center for Cancer Health Equity (CCHE) leads the Community Outreach and Engagement (COE) efforts for the OSUCCC. The CCHE is at the core of our COE efforts supporting the OSUCCC mission to reduce cancer health disparities throughout the CA. The CCHE is co- led by Darrell Gray II, MD, MPH, FACG (CC), who oversees the COE initiatives with the Clinical Trials Office to improve the accrual of women and minorities to clinical trials. COE works in the CA to connect minority populations to screening, outreach and engagement services. They also work with basic, clinical and population science program leaders in the OSUCCC to cultivate interest in CA-focused research including working with the Government Relations team and key faculty across the Center to pursue policy initiatives that address the cancer burden. COE efforts are supported by two Community Advisory Boards (rural and urban) that inform the focus and scope of CCHE activities and provide ongoing feedback to the OSUCCC leadership and Program leaders. The high priority cancers for the OSUCCC include lung, breast, colorectal, prostate, endometrial, cervical cancer, thyroid, and leukemia, as well as tobacco use, obesity and HPV vaccination. OSUCCC research and/or outreach and engagement efforts are ongoing to address these priority areas, via partnerships between the COE, OSUCCC research program members, and the community. To assess the impact of COE and OSUCCC efforts we have developed a logic model that includes short-term metrics of COE success: expanded reach (community members, patients); impact (services provided, time to diagnosis); collaborations (community partners, researchers); initiatives (grants funded); and clinical trial accrual (especially of underrepresented populations); and long-term metrics success including: reduced prevalence of risk factors and cancer rates, and longevity and impact of community partnerships. Over the last five years, we have had significant impact on HPV vaccination rates, accrual of minorities to clinical trials, breast cancer detection rates, navigation to screening and treatment, implementing translation for non-English speaking patients, fostering research to address the cancer burden in the CA. COE future plans focus on the priority cancers/risk behaviors of the OSUCCC as well as on 1) ensuring adequate communication between the community and the OSUCCC researchers as it relates to addressing the cancer burden in the catchment area and 2) a focus across the lifespan and expand to populations we are just beginning to work with (Asian, pediatric, rural clinics, LGBTQ) in order to reduce the cancer burden in our CA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089998
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Wang, Xinmei; Kwak, Kwang Joo; Yang, Zhaogang et al. (2018) Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma. PLoS One 13:e0198552
Callahan, Catherine L; Bonner, Matthew R; Nie, Jing et al. (2018) Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors. Environ Res 161:418-424
Gopalakrishnan, Bhavani; Cheney, Carolyn; Mani, Rajeswaran et al. (2018) Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget 9:9706-9713
Hankey, William; Frankel, Wendy L; Groden, Joanna (2018) Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev 37:159-172
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Stover, Daniel G; Parsons, Heather A; Ha, Gavin et al. (2018) Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol 36:543-553
Kelly, Rachel S; Lasky-Su, Jessica; Yeung, Sai-Ching J et al. (2018) Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One 13:e0197049
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Kim, Yangjin; Yoo, Ji Young; Lee, Tae Jin et al. (2018) Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc Natl Acad Sci U S A 115:4927-4932
Wani, Nissar Ahmad; Zhang, Bo; Teng, Kun-Yu et al. (2018) Reprograming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis. Mol Cancer Res 16:256-268

Showing the most recent 10 out of 2602 publications